© Reuters. FILE PHOTO: The emblem of Amazon is seen on the firm’s logistics centre in Boves, France, October 6, 2021 REUTERS/Pascal Rossignol/File Picture
By Foo Yun Chee
BRUSSELS (Reuters) -Amazon has not provided cures to handle considerations of EU antitrust regulators over its $1.4 billion acquisition of robotic vacuum maker iRobot (NASDAQ:), based on an replace on the European Fee web site.
The U.S. e-commerce large had till Wednesday to take action.
The European Fee’s competitors officers in November despatched a warning to the corporate that the deal may limit competitors available in the market for robotic vacuum cleaners, an indication that they needed cures from Amazon (NASDAQ:).
Amazon had been set to win unconditional EU clearance for the deal after the Fee’s legal professionals initially disagreed with such a warning, sources advised Reuters in November.
The legal professionals subsequently dropped their objections to such a cost sheet, often known as an announcement of objections.
The absence of cures may imply both unconditional EU antitrust approval or an EU veto of the deal.